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Background: Pemphigus vulgaris (PV) patients receiving immunosuppressive therapy may develop nail alter-
ations resulting from infection, skin disorder, or drug regimen.
Objective: This study aims to describe nail changes in PV female patients receiving immunosuppressive therapy
and to report the frequency of associated fungal and bacterial growth in the patients’ nails.
Methods: Twenty-ﬁve female PV patients who had at least one acquired ﬁnger or toenail abnormality and had
been administered at least one immunosuppressive drug were included in the study. Nail alterations were re-
corded. Nail scrapings were collected from abnormal nails for fungal and bacterial examination.
Results: Positive fungal and bacterial cultures were detected in 20 (80%) of patients’ nail samples. Five patients
reported nail alterations coinciding with disease onset, whereas 13 reported nail changes after administration
of immunosuppressive therapy.
Limitations: Lack of a control group (patients on similar immunosuppressive medications for conditions other
than PV) which would have further supported the ﬁndings demonstrated in this observational study.
Conclusion: Nail abnormalities in severe PV patients are frequently associated with fungal and bacterial growth.
Immunosuppressive therapy potentially initiates such changes.
© 2015 The Authors. Published by Elsevier Inc. on behalf ofWomen's Dermatologic Society. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Patients suffering from several dermatologic diseases may develop
nail abnormalities that are either related to their dermatoses, an associ-
ated systemic disease, a concurrent infection in the nail apparatus, or
drugs administered for their condition (de Berker and Baran, 2010;
Singh et al., 2005).
Pemphigus vulgaris (PV) patients occasionally present with associ-
ated, yet slightly variable, nail manifestations (Serratos and Rashid,
2009). The nail unit involvement can be a part of the initial presentation
of thedisease or occur during aﬂare alongwith other lesions. It has been
suggested that an increased frequency of onychomycosis in PV patients
may result from immunosuppressive therapy (Schlesinger et al., 2002).
Immunosuppressive therapy for PV includes systemic steroids (con-
ventional or pulse therapy), azathioprine, cyclophosphamide, myco-
phenolate mofetil, and cyclosporine (Tsuruta et al., 2012). Although
many of these drugs have demonstrated potent efﬁcacy in the treat-
ment of nail manifestations in PV (Serratos and Rashid, 2009), several
reports indicate that these drugsmay induce a variety of nail alterations
(Rault, 2000; Tosti et al., 2001).interest.
t).
Inc. on behalf of Women's DermatThe current study describes nail changes in female PV patients re-
ceiving immunosuppressive therapy and reports the frequency of asso-
ciated fungal and bacterial growth in the patients’ nails.
Methods
The study was approved by the Dermatology Research Ethical Com-
mittee (REC), Faculty of Medicine, Cairo University and is in accordance
with the Helsinki Declaration of 1975. It included 25 female PV patients
from the dermatology inpatient ward of Kasr AL-Ainy Hospital, Faculty
of Medicine, Cairo University. All recruited patients required admission
to the inpatient ward, either because of the severity of the disease or for
therapeutic intervention; had at least one acquired ﬁnger or toenail ab-
normality; and had been administered at least one immunosuppressive
drug. Pemphigus vulgaris was diagnosed based on classic clinical and
histopathological features. All patients were examined thoroughly,
with special emphasis on nail abnormalities. All participants were
asked to sign an informed consent before admission into the study.
Patientswith a knownhistory of nail disease forwhich they received
treatment were not included. In addition, patients with associated
nondermatologic conditions that are known to cause nail alterations,
such as diabetes, renal failure, advanced liver disease, and peripheral
vascular disease, were also excluded from the study. Patients who de-
veloped steroid-induced diabetes were not excluded.ologic Society. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Frequency of Nail Changes in Pemphigus Vulgaris Patients.
Clinical Nail Finding No. of Patients (Percentage of Total)
Subungal hyperkeratosis 16 (64%)
Onycholysis 16 (64%)
Onychorrhexis 13 (52%)
Brittleness 8 (32%)
Yellow discoloration 11 (44%)
Total dystrophy 3 (12%)
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each patient, with a special emphasis on the history of the associated
nail changes. General physical and dermatological examinations were
performed and all nail abnormalities were recorded for each patient.
Nail scrapings were collected from the deeper layers of the abnormal
nails of all recruitswith a No. 11 scalpel blade and sent to the lab for fun-
gal and bacterial examination and culture.
Laboratory diagnosis
Microscopic examination
Thin nail pieces were placed on a slide under a cover slip in KOH,
heated gently, and examined under low- and high-power on a micro-
scope with a reduced light source. Young hyphae appear in the speci-
men as long, undulant, branching threads, and older hyphae break
down into arthrospores.
Direct culture
Each sample was cultured in mycological media for dermatophytes
and bacteriological media for bacteria as follows.
Mycological media culture. Screwcapped bottles of Sabouraud's dextrose
agar containing 0.05 mg/ml of chloramphenicol and 0.1 mg/ml of
cyclohexamide were prepared, and the pH was adjusted to 6.5 to 7.0.
Nail scrapings were imbedded in the media and incubated at 22 to
30°C for 2 to 3 weeks. The cultures were examined soon after sporula-
tion, as dermatophytes macroconidia are more easily observed in the
ﬁrst few days of sporulation compared with old cultures.
Fungal growth was identiﬁed according to:
1. Fungal growth pattern.
2. Surface color and growth reversal.
3. Microscopic examination of the macroconidia and conidiophore.
Bacteriological culture
Blood agar plates were prepared, inoculatedwith nail scrapings, and
incubated at 37°C for 24 hours.
Bacterial growth was identiﬁed by routine methods (e.g., morphology,
culture characteristics, biochemical reactions, and serological identiﬁcation).
Statistical methods
The data are statistically described as themean± standard deviation
(± SD), range, frequency (number of cases), and percentage, where ap-
propriate. Comparisons of the numerical variables between the study
groups were performed with the Chi square (χ2) test. Alternatively,
the exact test was used when the expected frequency was less than
ﬁve. P values less than 0.05 were considered statistically signiﬁcant.
All statistical calculations were performed with SPSS version 15.0
(SPSS Inc., Chicago, Illinois).
Results
The study included 25 female PV patients, aged between 20 and 65
years (mean = 45.5, SD ± 13.7). The disease duration ranged between
1.92 and 120months (mean= 34.8, SD ± 30) and the treatment dura-
tion ranged between 1 and 120months (mean= 24.4, SD± 28.2). The
duration of nail afﬂiction ranged between 0.96 and 60months (mean=
18, SD ± 15.6).
All patients exclusively received high-dose systemic steroids in the
form of intravenous (IV) pulse steroid therapy (500mg IVmethyl pred-
nisolone for 3 consecutive days plus 500 mg IV cyclophosphamide for
one day) every 2 to 4 weeks.
The number of nails affected with any type of abnormality differed
among patients. The frequency of nail alteration ranged between 2and 20 nails per patient (mean = 9, SD ± 6). Toenail abnormalities
were observed in 21 (84%) patients. Speciﬁcally, 15 patients displayed
bilateral toenail alterations. Fingernail abnormalities were observed in
20 (80%) patients, with 18 of these patients displaying bilateral ﬁnger-
nail alterations. Of the 25 PV patients, 16 (64%) patients displayed
both ﬁngernail and toenail alterations, 5 (20%) patients exclusively
displayed toenail alterations, and4 (16%) patients exclusively presented
with ﬁngernail changes.
The most common nail alterations were onycholysis, subungual hy-
perkeratosis, onychorrhexis, and discoloration. Brittleness and total
dystrophywere observed to a lesser extent. No signiﬁcant difference be-
tween the total number of nails affected in the ﬁngers or toes was ob-
served (P = 0.182). The frequency of nail abnormalities detected in
patients is presented in Table 1.
Positive culture results were observed in 20 patients. Six (24%) pa-
tients displayed fungal culture growth, 6 (24%) patients demonstrated
positive bacterial culture growth, and 8 (32%) patients demonstrated
both positive fungal and bacterial growth. No bacterial or fungal growth
was detected in 5 (20%) patients. Staphylococcus aureus and
Microsporum canis were the most commonly isolated pathogens. The
frequency of bacterial and fungal growth is shown in Table 2.
The onset of nail abnormalities was determined by patient observation
in18cases. Fivepatientswithnail samples thatdemonstratednogrowthon
culture reported that their nail changes coincided with or started shortly
after the onset of PV, while 8 patients with nail samples that demonstrated
both fungal and bacterial growth on culture reported that their nail abnor-
malities developed at least 1 year following the initiation of immunosup-
pressive therapy. The remaining ﬁve reported that their nail abnormalities
occurred sometime following the start of systemic immunosuppressive
therapy. Seven patients could not report the onset of their nail affection.
Pemphigus vulgaris disease and treatment durations did not signiﬁ-
cantly inﬂuence the results of fungal or bacterial cultures (P= 0.086 and
0.063, respectively). In addition, the total number of digits affected and
theduration of nail disease displayedno signiﬁcant difference betweenpa-
tients with positive cultures and those with negative cultures (P= 0.968
and0.462, respectively). On the other hand, both PVdisease and treatment
duration signiﬁcantly positively correlated to nail disease duration (P=
0.001, r= 0.795 and P=0.001, r= 0.748, respectively) (Fig. 1).
Discussion
Several dermatologic diseases are associated with nail apparatus ab-
normalities. The nail alterations described in PV patients include
onychomadesis, onycholysis, cross-ridging, pitting, Beau’s lines,
subungual hemorrhage, paronychia, nail dystrophy, and nail plate dis-
coloration (de Berker et al., 1993; Engineer et al., 2000; Kim et al., 1996).
In the current work, subungual hyperkeratosis, onycholysis, and
onychorrhexis were the most common nail alterations observed in
Egyptian PV female patients. Schlesinger et al. (2002) reported 30 PV
patients presenting with nail alterations, such as paronychia, discolor-
ation, onychomadesis, subungual hemorrhage, onycholysis, subungual
hyperkeratosis, deformation and onychorrhexis. In the current study,
we also noted brittleness in 8 (32%) patients and total nail dystrophy
in 3 (12%) patients, which may correspond with previous authors’ clas-
siﬁcations of deformation.We did not observe paronychia or subungual
hemorrhage in any of our PV patients undergoing treatment.
Table 2
Type and Frequency of Bacterial and Fungal Growth Observed in Patients’ Nails.
Fungus Positive
Culture
Bacteria Positive
Culture
Microsporum canis 5 (20%) Staphylococcus aureus 5 (20%)
Microsporum audouinii 4 (16%) Streptococcus pyogenes 3 (12%)
Trichophyton rubrum 2 (8%) Escherichia coli 2 (8%)
Trichophyton concentricum 3 (12%) Klebsiella pneumoniae 2 (8%)
Total positive growth 14 (56%) Streptococcus haemolyticus 1 (4%)
Staphylococcus epidermidis 1 (4%)
Total positive growth 14 (56%)
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growth, the most frequent beingM. canis. Similarly, 53% of the PV patients
reported by Schlesinger et al. (2002) displayed a positive fungal culture but
exclusively grew Trichophyton rubrum in culture. The difference in the fre-
quency of dermatophytes involved in the current study could be attributed
to the fact that dermatophytes species vary geographically (Aboueisha and
El-Mahallawy, 2013).
Schlesinger et al. (2002) attributed the high frequency of
onychomycosis to therapeutic immunosuppression in those patients.
Bacterial cultures from abnormal nails were positive in 14 (56%) out
of 25 PV patients. Cahali et al. (2002) reported S. aureuspositive cultures
in 2 out of 5 PV patients and paronychia was the primary nail alteration.
Although S. aureus was the most common bacteria in our PV patients,
bacterial cultures also demonstrated the presence of other organisms.
Similar to onychomycosis (Schlesinger et al., 2002), the increased bacte-
rial growth on culture may also be related to immunosuppression.
Furthermore, in 13 (72%) out of 18 cases with reliable histories, the nail
alterations occurred after receiving one ormore immunosuppressive drugs.
The cultures of all 13 patients were positive for bacteria, fungi, or both. In-
terestingly, an interval of at least 1 year between the initiation of immuno-
suppressive therapy and the onset of nail alterations was observed in 8
cases, despite PV stabilization or improvement. This observation mayFig. 1. Correlation between nail disease duration and pemphigus vulgaris disease (a) and
treatment (b) durations.point to the notion that immunosuppressive drugs administered to PV pa-
tients can indirectly cause increasednail fungal andbacterial contamination
as a consequence of generalized immunosuppression.
On the other hand, nail abnormalities appeared to coincide with or
occur shortly after the onset of PV in 20% of our patients. Interestingly,
these patients did not display any fungal or bacterial growth on culture,
suggesting that early nail alterations in PV patients potentially result
from their disease rather than immunosuppression or drug therapy.
This ﬁnding is in agreement with the report by Schlesinger et al.
(2002) that demonstrated that 14 (46%) of 30 patients with nail chang-
es attributed to PV displayed negative fungal cultures. In contrast to the
results of the previous authors, who reported that nail changes in PV ex-
clusively affect ﬁngernails, nail changes due to PV affected both ﬁnger-
nails and toenails almost equally.
Our results suggest that nail abnormalities in PV may be related to
dermatologic disease in 20% of cases and immunosuppressive therapy
in at least 52% of cases. However, whether bacterial and/or fungal infec-
tion of the nail is precipitated by drug therapy or the dermatological dis-
ease itself remains unclear and requires further study. Moreover, the
degree of participation of these microbes in nail morphology distortion
in PV patients remains to be elucidated.
In contrast to previous PV reports that imply that ﬁngernails are
more often involved than toenails (Engineer et al., 2000), toenail abnor-
malitieswere slightlymore common thanﬁngernail abnormalities in PV
patients in this study. Moreover, Cahali et al. (2002) reported that no
patient exclusively displayed toenail alterations in their series of ﬁve
PV patients,whereaswe observed 5 patientswith toenail alterations ex-
clusively and 4 patients with only ﬁngernail afﬂiction.
The signiﬁcantly positive correlationbetween thedurationof nail alter-
ations and PV duration as well as treatment duration may provide further
insight into the etiopathogenesis of nail dystrophy associatedwith PV. The
former correlation suggests apotential clue for the intertwined relationbe-
tween PV and clinical nail involvement. However, this ﬁnding contradicts
what was reported by Schlesinger et al. (2002), who suggested that nail
changes in PV patients do not correlate with the disease’s duration.
The results of this study suggest that nail abnormalities in severe PV pa-
tients requiring hospitalization and immunosuppressive treatment are com-
monly associated with fungal and bacterial growth. The most common
abnormalities are onycholysis and subungual hyperkeratosis. The duration
of disease appears to dictate the longevity of nail changes in our patients,
and immunosuppressive therapy may initiate these nail changes either
alone or as a result of opportunistic bacterial and/or fungal growth affecting
the nail unit. Accordingly, prompt treatment of PV utilizing amultidisciplin-
ary approach (combinedor sequential therapy)would presumably decrease
the incidenceofnail affection inPVpatients on immunosuppressive therapy.References
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